 "Pfizer vaccine")
Pfizer and partner BioNTech SE said their Covid-19 vaccine was safe and produced strong antibody responses in children ages 5 to 11 in a large-scale trial, findings that could pave the way to begin vaccinating grade-school kids within months.
The long-awaited results offer one of the first looks at how well a Covid vaccine could work for younger children.
Pressure to immunise kids has been on the climb in the US, where a new school year has started just as the delta variant is fueling a surge in cases.
In a trial with 2,268 participants, two shots of a 10 microgram dose —
